Amgen Repatha cut all-cause mortality 20% in high-risk adults in Phase 3 primary prevention analysis

 

Amgen says Repatha cut all-cause mortality 20% in high-risk adults in Phase 3 VESALIUS-CV primary prevention analysis

• Result comes from a pre-specified Phase 3 VESALIUS-CV analysis in high-risk adults without prior heart attack or stroke.
• Amgen says this is the first demonstrated mortality benefit for a PCSK9 in primary prevention patients.

https://finviz.com/stock?t=AMGN&p=d